CA2647542A1 - Reagents and methods for cancer treatment and prevention - Google Patents

Reagents and methods for cancer treatment and prevention Download PDF

Info

Publication number
CA2647542A1
CA2647542A1 CA002647542A CA2647542A CA2647542A1 CA 2647542 A1 CA2647542 A1 CA 2647542A1 CA 002647542 A CA002647542 A CA 002647542A CA 2647542 A CA2647542 A CA 2647542A CA 2647542 A1 CA2647542 A1 CA 2647542A1
Authority
CA
Canada
Prior art keywords
cells
thapsigargin
cancer cells
cancer
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002647542A
Other languages
English (en)
French (fr)
Inventor
Kayvan R. Niazi
Shahrooz Rabizadeh
Dale E. Bredesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Buck Institute for Research on Aging
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2647542A1 publication Critical patent/CA2647542A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002647542A 2006-03-27 2007-03-27 Reagents and methods for cancer treatment and prevention Abandoned CA2647542A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/389,695 2006-03-27
US11/389,695 US9107863B2 (en) 2006-03-27 2006-03-27 Reagents and methods for cancer treatment and prevention
PCT/US2007/007526 WO2007126787A2 (en) 2006-03-27 2007-03-27 Reagents and methods for cancer treatment and prevention

Publications (1)

Publication Number Publication Date
CA2647542A1 true CA2647542A1 (en) 2007-11-08

Family

ID=38533710

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002647542A Abandoned CA2647542A1 (en) 2006-03-27 2007-03-27 Reagents and methods for cancer treatment and prevention

Country Status (8)

Country Link
US (4) US9107863B2 (cg-RX-API-DMAC10.html)
EP (2) EP2004219B1 (cg-RX-API-DMAC10.html)
JP (2) JP5422377B2 (cg-RX-API-DMAC10.html)
CN (1) CN101443036A (cg-RX-API-DMAC10.html)
AU (1) AU2007245169B2 (cg-RX-API-DMAC10.html)
CA (1) CA2647542A1 (cg-RX-API-DMAC10.html)
ES (2) ES2548435T3 (cg-RX-API-DMAC10.html)
WO (1) WO2007126787A2 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376495B2 (ja) 1992-08-18 2003-02-10 ソニー株式会社 接着剤の塗布方法及び接着治具
US9107863B2 (en) 2006-03-27 2015-08-18 The Buck Institute For Age Reasearch Reagents and methods for cancer treatment and prevention
CZ300806B6 (cs) * 2007-07-18 2009-08-12 Ústav experimentální mediciny AV CR, v.v.i. Imunostimulacní úcinky trilobolidu a zpusob jeho prípravy
US9446141B2 (en) * 2013-03-15 2016-09-20 Genspera, Inc. Methods of producing cancer compounds
EP2796137A1 (en) * 2013-04-22 2014-10-29 Universität des Saarlandes SERCA inhibitor and Calmodulin antagonist combination
CN112891354B (zh) * 2021-03-18 2022-10-21 新乡医学院 MDM2抑制剂Nutlin-3a在制备激活内质网应激诱导的癌细胞凋亡药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
IN165717B (cg-RX-API-DMAC10.html) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
AU5458500A (en) 1999-06-02 2000-12-18 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
JP2001010973A (ja) * 1999-06-29 2001-01-16 Dnavec Research Inc がんワクチン
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US7056491B2 (en) * 2000-11-08 2006-06-06 Wisconsin Alumni Research Foundation Monoterpenes and sesquiterpenes as chemotherapeutic and radiation sensitizers and immunomodulators
CA2356438A1 (en) * 2001-09-05 2003-03-05 Andre Pichette Use of terpenes and derivatives as potentiators of antitumor agents in the treatment of cancers
US7402406B2 (en) * 2001-10-31 2008-07-22 Astellas Pharma Inc. Methods of evaluating phosphatase inhibitors
WO2003087129A2 (en) * 2002-04-08 2003-10-23 Siga Technologies, Inc. Immunogenic peptides, and method of identifying same
US20060148064A1 (en) 2002-10-25 2006-07-06 Srivastava Pramod K Apparatus and method for immunotherapy of a cancer through controlled cell lysis
WO2005051423A2 (en) * 2003-11-30 2005-06-09 Yeda Research And Development Co. Ltd Methods and agents for immune modulation and methods for identifying immune modulators
US9107863B2 (en) * 2006-03-27 2015-08-18 The Buck Institute For Age Reasearch Reagents and methods for cancer treatment and prevention

Also Published As

Publication number Publication date
US9885704B2 (en) 2018-02-06
US8895031B2 (en) 2014-11-25
EP2004219A4 (en) 2010-06-30
AU2007245169A1 (en) 2007-11-08
ES2548435T3 (es) 2015-10-16
WO2007126787A2 (en) 2007-11-08
US20100278874A1 (en) 2010-11-04
EP2974738A1 (en) 2016-01-20
CN101443036A (zh) 2009-05-27
US20070224207A1 (en) 2007-09-27
EP2004219A2 (en) 2008-12-24
EP2004219B1 (en) 2015-09-16
ES2655909T3 (es) 2018-02-22
JP5422377B2 (ja) 2014-02-19
US9107863B2 (en) 2015-08-18
WO2007126787A3 (en) 2008-10-23
AU2007245169B2 (en) 2012-05-24
EP2974738B1 (en) 2017-11-15
US20180128816A1 (en) 2018-05-10
JP5712257B2 (ja) 2015-05-07
US20160069864A1 (en) 2016-03-10
JP2014028815A (ja) 2014-02-13
JP2009535298A (ja) 2009-10-01

Similar Documents

Publication Publication Date Title
US20180128816A1 (en) Reagents and Methods for Cancer Treatment and Prevention
Son et al. Immunogenic cell death induced by ginsenoside Rg3: significance in dendritic cell-based anti-tumor immunotherapy
Morel et al. The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity
Wagner et al. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA
US20190117685A1 (en) Process for the identification of compounds for treating cancer
TW201924722A (zh) 用於刺激第i型干擾素基因之方法及包含陽離子脂質的組合物
Paget et al. Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxynucleotides
US20230233474A1 (en) Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
Yan et al. Bryostatin-I: a dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine
EP4327821A1 (en) Immuno-oncology therapeutic composition using adjuvant including lipopeptides and poly (i:c)
KR102352715B1 (ko) Il-21을 이용한 항원 특이적 cd8+ t 세포의 증식 촉진 또는 대량 배양 방법
HK40105290A (en) Immuno-oncology therapeutic composition using adjuvant including lipopeptides and poly (i:c)
Yamaoka et al. WS/PP-024b-11 Spatiotemporal regulation of heat shock protein 90-chaperoned self-DNA and CpG-oligodeoxynucleotide for type-I interferon induction via targeting to static early endosome Y. Tamura, K. Saito, K. Okuya, T. Torigoe, N. Sato. Sapporo Medical University School of Medicine, Sapporo, Japan
Molavi Delivery of STAT3 inhibitor cucurbitacins to tumor by polymeric nano-carriers: Implications in cancer chemo-and immunotherapy

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130327